Condition: Solid Tumor Malignancies · Brain Metastasases · Leptomeningeal Disease (LMD) · Sponsor: Sunnybrook Health Sciences Centre
This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease involvement, including leptomeningeal disease (Cohort A), parenchymal brain metastases (Cohort B), and no evidence of CNS metastases (Cohort C).
This description comes directly from the study's public registry record.
Katarzyna Jerzak, Dr · 416-480-5000 · katarzyna.jerzak@sunnybrook.ca
Always discuss trial participation with your own doctor first.
| Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07476781